Novo Nordisk A/S
(WBO:NNO2)
€
121.88
-1.48 (-1.2%)
Market Cap: 544.17 Bil
Enterprise Value: 543.42 Bil
PE Ratio: 45.42
PB Ratio: 36.10
GF Score: 86/100 - Q2 2024 Novo Nordisk A/S Earnings Call TranscriptAug 07, 2024€111.6 (-6.04%)Earnings
- Q1 2024 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 03, 2024€114.1 (-2.21%)Earnings
- Q1 2024 Novo Nordisk A/S Earnings Call TranscriptMay 02, 2024€116.68 (-0.70%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 21, 2024
- Novo Nordisk A/S Capital Markets Day TranscriptMar 07, 2024
- Q4 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 01, 2024€105.6 (+0.06%)Earnings
- Q4 2023 Novo Nordisk A/S Earnings Call TranscriptJan 31, 2024€105.54 (+4.97%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Novo Nordisk A/S at American Heart Association Conference TranscriptNov 11, 2023
- Q3 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 03, 2023€91.6 (-3.92%)Earnings
- Q3 2023 Novo Nordisk A/S Earnings Call TranscriptNov 02, 2023€95.34 (+3.41%)Earnings
- Q2 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 11, 2023€83.4 (-0.82%)Earnings
- Q2 2023 Novo Nordisk A/S Earnings Call TranscriptAug 10, 2023€84.09 (-0.66%)Earnings
- Novo Nordisk A/S R&D Investor Call TranscriptJun 26, 2023
- Q1 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 09, 2023€76.36 (-1.01%)Earnings
- Q1 2023 Novo Nordisk A/S Earnings Call TranscriptMay 04, 2023€76.06Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 23, 2023
- Q4 2022 Novo Nordisk A/S Earnings Call TranscriptFeb 01, 2023€63.18 (-0.09%)Earnings
- Q3 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 03, 2022€58.14 (+0.43%)Earnings
- Q3 2022 Novo Nordisk A/S Earnings Call TranscriptNov 02, 2022€57.89 (+7.56%)Earnings
- Novo Nordisk A/S at JPMorgan CEO Call Series TranscriptSep 14, 2022
- Q2 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 05, 2022€50.72 (-0.82%)Earnings
- Q2 2022 Novo Nordisk A/S Earnings Call TranscriptAug 03, 2022€51.71 (-9.49%)Earnings
- Novo Nordisk A/S Investor and Analyst Event at ADA TranscriptJun 06, 2022
- Q1 2022 Novo Nordisk A/S Earnings Presentation - London TranscriptMay 05, 2022
- Q1 2022 Novo Nordisk A/S Earnings Call TranscriptApr 29, 2022€51.93Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 24, 2022
- Novo Nordisk A/S Capital Markets Day TranscriptMar 03, 2022
- Q4 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 04, 2022€43.82 (-3.96%)Earnings
- Q4 2021 Novo Nordisk A/S Earnings Call TranscriptFeb 02, 2022€46.79 (+4.40%)Earnings
- Novo Nordisk A/S to Discuss Supply Challenges for Wegovy Call TranscriptDec 20, 2021
- Q3 2021 Novo Nordisk A/S Earnings Presentation (London-Based Investors) TranscriptNov 04, 2021
- Q3 2021 Novo Nordisk A/S Earnings Call TranscriptNov 03, 2021€48.77 (+2.85%)Earnings
- Q2 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 06, 2021€42.26 (-2.10%)Earnings
- Q2 2021 Novo Nordisk A/S Earnings Call TranscriptAug 04, 2021€40.93 (+4.35%)Earnings
- Novo Nordisk A/S R&D Investor Call TranscriptJun 28, 2021
- Novo Nordisk A/S Approval of Wegovyâ„¢ in the United States Investor Call TranscriptJun 07, 2021
- Novo Nordisk A/S to Discuss International Operations Call TranscriptMay 21, 2021
- Q1 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 06, 2021€30.63 (-0.91%)Earnings
- Q1 2021 Novo Nordisk A/S Earnings Call TranscriptMay 05, 2021€30.91 (-0.55%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 25, 2021
- Q4 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 05, 2021€29.67 (-1.77%)Earnings
- Q4 2020 Novo Nordisk A/S Earnings Call TranscriptFeb 03, 2021€30.21 (+2.62%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Novo Nordisk A/S to Announce the Decision to Enter the Phase 3 Development in Alzheimer's Disease with Oral Semaglutide Call TranscriptDec 16, 2020
- Novo Nordisk A/S ESG Conference Call TranscriptNov 30, 2020
- Q3 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 02, 2020€27.91 (+0.83%)Earnings
- Q3 2020 Novo Nordisk A/S Earnings Call TranscriptOct 30, 2020€27.68 (-3.13%)Earnings
- Novo Nordisk A/S to Discuss Updated 2020 Outlook Call TranscriptOct 09, 2020
- Q2 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 07, 2020€27.5 (+2.25%)Earnings
- Q2 2020 Novo Nordisk A/S Earnings Call TranscriptAug 06, 2020€26.9 (-1.63%)Earnings
- Novo Nordisk A/S Virtual R&D Investor Call (Q&A) TranscriptJun 19, 2020
- Novo Nordisk A/S Virtual R&D Investor Presentation TranscriptJun 19, 2020
- Novo Nordisk A/S at UBS Global Healthcare Conference (Virtual) TranscriptMay 20, 2020
- Q1 2020 Novo Nordisk A/S Earnings Presentation TranscriptMay 07, 2020
- Q1 2020 Novo Nordisk A/S Earnings Call TranscriptMay 06, 2020€28.96 (-0.46%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 26, 2020
- Q4 2019 Novo Nordisk A/S Earnings Presentation TranscriptFeb 06, 2020
- Q4 2019 Novo Nordisk A/S Earnings Call TranscriptFeb 05, 2020€29.19 (+4.34%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- Novo Nordisk A/S Capital Markets Day TranscriptNov 20, 2019
- Dicerna Pharmaceuticals Inc to Discuss Collaboration with Novo Nordisk A/S Conference Call TranscriptNov 18, 2019
- Q3 2019 Novo Nordisk A/S Earnings Presentation TranscriptNov 04, 2019
- Q3 2019 Novo Nordisk A/S Earnings Call TranscriptNov 01, 2019€25.72 (+4.96%)Earnings
- Novo Nordisk A/S to Discuss Rybelsus® US Approval Call TranscriptSep 23, 2019
- Q2 2019 Novo Nordisk A/S Earnings Presentation TranscriptAug 12, 2019
- Q2 2019 Novo Nordisk A/S Earnings Call TranscriptAug 09, 2019€22.34 (-0.52%)Earnings
- Novo Nordisk A/S Investor and Analyst Event at ADA 2019 TranscriptJun 10, 2019
- Q1 2019 Novo Nordisk A/S Earnings Presentation TranscriptMay 07, 2019
- Q1 2019 Novo Nordisk A/S Earnings Call TranscriptMay 03, 2019€21.3 (-2.87%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 21, 2019
Novo Nordisk A/S Virtual R&D Investor Call (Q&A) Transcript
Jun 19, 2020 / 02:00PM GMT
Release Date Price:
€30.06
(+1.90%)
Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board
/- -
Welcome back to the Novo Nordisk virtual R&D investor presentation. Now we're on to the Q&A session. (Operator Instructions)
And then I will orchestrate the meeting from here.
Questions & Answers
Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board
/- -
(Operator Instructions) So we're ready to take the first question. And the first question goes to Martin Parkhøi from Danske Bank.
Martin ParkhÃ;i;S
Danske Bank A;Research Division - Senior Equity Analyst
¸ - / -
As Karsten said, it's Martin Parkhøi from Danske Bank. Firstly, I think is focused on the obesity mass. I guess, the Phase I trial that was in a loose combination. Could you talk a bit about the device for later-stage trials? We know it needs to be a dual-chamber device, but
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)